医学临床研究
  2025年4月5日 星期六           首 页    |    期刊简介    |    编委会    |    投稿指南    |    期刊订阅    |    广告合作    |    留言板    |    联系我们    |    English
医学临床研究  2022, Vol. 39 Issue (7): 973-976    DOI: 10.3969/j.issn.1671-7171.2022.07.004
  论著 本期目录 | 过刊浏览 | 高级检索 |
RASSF1A和WIF-1基因甲基化程度与直肠癌患者新辅助放化疗疗效的关系
张荣枝, 荆威**
安康市中医医院肛肠病院,陕西 安康 725000
Relationship between the Methylation Degree of RASSF1A and WIF-1 Genes and the Efficacy of Neoadjuvant Radiotherapy and Chemotherapy in Rectal Cancer Patients
ZHANG Rong-zhi, JING Wei
Anorectal Hospital,Ankang Hospital of Traditional Chinese Medicine,Ankang Shaanxi 725000
全文: PDF (1147 KB)   HTML (1 KB) 
输出: BibTeX | EndNote (RIS)      
摘要 【目的】探讨血清Ras相关区域家族1A基因(RASSF1A)和Wnt抑制因子-1(WIF-1)基因甲基化程度与直肠癌患者新辅助放化疗(nCRT)疗效的关系。【方法】选取本院收治的109例直肠癌患者为研究对象,均给予nCRT治疗。分析患者治疗效果,根据肿瘤消退程度分级(TRG)标准分为观察组(nCRT敏感,n=73)和对照组(nCRT不敏感,n=36)。收集两组患者年龄、性别、肿瘤距离肛门位置、分化类型、临床分期、淋巴结转移及合并疾病等临床资料,对比两组血清RASSF1A和WIF-1基因甲基化阳性表达率,分析RASSF1A和WIF-1基因甲基化程度与直肠癌患者nCRT疗效的相关性。【结果】两组年龄、性别、肿瘤距离肛门位置、分化类型、临床分期、淋巴结转移、合并疾病构成比及血压、血脂水平相比较,差异无统计学意义(P>0.05)。观察组血清RASSF1A基因阳性率为16.44%(12/73)、WIF-1基因甲基化阳性率为13.70%(10/73),均低于对照组的41.67%(15/36)和33.33%(12/36),且差异均有统计学意义(P<0.05)。经Spearman检验,血清RASSF1A和WIF-1基因甲基化程度与疗效呈负相关(P<0.01)。【结论】RASSF1A和WIF-1基因甲基化程度与直肠癌患者nCRT疗效关系密切,RASSF1A和WIF-1基因甲基化阳性率越高,患者nCRT疗效越低。
服务
把本文推荐给朋友
加入我的书架
加入引用管理器
E-mail Alert
RSS
作者相关文章
张荣枝
荆威
关键词 直肠肿瘤/病理学肿瘤抑制蛋白质类/遗传学甲基化化放疗    
Abstract:【Objective】 To investigate the relationship between the methylation of Ras related region family 1A gene (RASSF1A) and Wnt inhibitor factor-1(WIF-1) gene in serum and the efficacy of neoadjuvant radiotherapy and chemotherapy (nCRT) in patients with rectal cancer. 【Methods】A total of 109 patients with rectal cancer in our hospital were selected as the study subjects,and all of them were treated with nCRT. The treatment effect was analyzed. The patients were divided into observation group (nCRT sensitive,n=73) and control group (nCRT insensitive,n=36) according to the tumor regression grade (TRG) standard; The age,sex,tumor distance from anal position,differentiation type,clinical stage,lymph node metastasis and associated diseases of the two groups were collected,and the positive expression rates of RASSF1A and WIF-1 gene methylation in the two groups were compared,the correlation between the methylation degree of RASSF1A and WIF-1 genes and the efficacy of nCRT in rectal cancer patients were analyzed. 【Results】 There was no significant difference between the two groups in age,sex,distance from the tumor to the anal position,differentiation type,clinical stage,lymph node metastasis,combined disease constituent ratio,blood pressure and blood lipid level (P>0.05). The positive rates of RASSF1A gene and WIF-1 gene methylation in serum of the observation group were 16.44% (12/73) and 13.70% (10/73),both lower than 41.67% (15/36) and 33.33% (12/36) of the control group (P<0.05). Spearman test showed that the methylation degree of RASSF1A and WIF-1 genes in serum was negatively correlated with the curative effect (P<0.01). 【Conclusion】The degree of methylation of RASSF1A and WIF-1 genes is closely related to the efficacy of NCRT in patients with rectal cancer. The higher the positive rate of methylation of RASSF1A and WIF-1 genes,the lower the efficacy of NCRT in patients with rectal cancer.
Key wordsRectal Neoplasms/PA    Tumor Suppressor Proteins/GE    Methylation    Chemoradiotherapy
收稿日期: 2022-01-10     
中图分类号:  R735.37  
基金资助:陕西省中医药管理局科研项目(2019-GJ-JC017)
通讯作者: **E-mail:583633815@qq.com   
引用本文:   
张荣枝, 荆威. RASSF1A和WIF-1基因甲基化程度与直肠癌患者新辅助放化疗疗效的关系[J]. 医学临床研究, 2022, 39(7): 973-976.
ZHANG Rong-zhi, JING Wei. Relationship between the Methylation Degree of RASSF1A and WIF-1 Genes and the Efficacy of Neoadjuvant Radiotherapy and Chemotherapy in Rectal Cancer Patients. JOURNAL OF CLINICAL RESEARCH, 2022, 39(7): 973-976.
链接本文:  
http://journal07.magtech.org.cn/yxlcyj/CN/10.3969/j.issn.1671-7171.2022.07.004     或     http://journal07.magtech.org.cn/yxlcyj/CN/Y2022/V39/I7/973
版权所有 © 2013 医学临床研究杂志社  湘ICP备13012052号-1
办公地址:湖南省长沙市芙蓉区新军路43号煤炭大院主办公楼6楼621、623、632、636室 邮编:410011 电话(传真):0731-84824007 E-mail:jcr_cs.hn@vip.163.com
技术支持:北京玛格泰克科技发展有限公司 技术支持:support@magtech.com.cn